Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

Cardiac autonomic testing and diagnosing heart disease. “A clinical perspective”

Nicholas L. DePace, Sr, Joy P. Mears, Michael Yayac, Joseph Colombo
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 16th 2018 Heart International. 2014;9(2):37-44 DOI: https://doi.org/10.5301/heartint.5000218
Select a Section…
1

Abstract

Overview

Background. Coronary heart disease (CHD) is a major health concern, affecting nearly half the middle-age population
and responsible for nearly one-third of all deaths. Clinicians have responsibilities beyond diagnosing CHD,
including risk stratification of patients for major adverse cardiac events (MACE), modifying the risks and treating the
patient. In this first of a two-part review, identifying risk factors is reviewed, including more potential benefit from
autonomic testing.
Methods. Traditional and non-traditional, and modifiable and non-modifiable risk factors for MACE where compared,
including newer risk factors, such as inflammation, carotid intimal thickening, ankle-brachial index, CT
calcium scoring, and autonomic function testing, specifically independent measurement of parasympathetic and
sympathetic (P&S) activity.
Results. The Framingham Heart Study, and others, have identified traditional risk factors for the development of
CHD. These factors effectively target high-risk patients, but a large number of individuals who will develop CHD
and MACE are not identified. Many patients with CHD who appear to be well-managed by traditional therapies
still experience MACE. In order to identify these patients, other possible risk factors have been explored. Advanced
autonomic dysfunction, and its more severe form, cardiac autonomic neuropathy, have been strongly
associated with an elevated risk of cardiac mortality and are diagnosable through P&S testing.
Conclusions. Independent measures of P&S activity, provides additional information and has the potential to incrementally
add to risk assessment. This additional information enables physicians to (1) specifically target more
high-risk patients and (2) titrate therapies, with autonomic testing guidance, in order to minimize risk of cardiac
mortality and morbidity.

Keywords

Cardiac autonomic neuropathy, Cardiovascular risk factors, Heart disease, Mortality

2

Article Information

Disclosure

Financial support: No grants or funding have been received for this
study.

Correspondence

Nicholas L. DePace, Sr. M.D. 438 Ganttown Rd., Ste. 8 & 9 Sewell, NJ 08080, USA dovetech@erols.com

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup